The links listed below will connect you to professional medical organizations, hospitals, national and international Gaucher disease groups, patient support organizations, and medical centers specializing in Gaucher disease care and research.
Comprehensive information on Gaucher disease and its management from Genzyme.
National Organization for Rare Disorders, Inc.
A non-profit federation of voluntary health organizations dedicated to helping people with rare "orphan" diseases and assisting the organizations that serve them.
The world's leading nonprofit health advocacy organization committed to transforming health through genetics.
National Gaucher Foundation (USA)
A national non-profit organization that funds research, offers financial assistance, promotes education and awareness, supports legislative issues and provides outreach programs
The largest patient registry for Gaucher disease, sponsored and administered by Genzyme.
National Tay-Sachs & Allied Diseases Association
An organization established to lead the fight to treat and cure Tay-Sachs, Canavan and related genetic diseases and to support affected families and individuals in leading fuller lives.
Society for Inherited Metabolic Disorders
A non-profit professional organization whose purpose is to promote the worldwide advancement of research and medical treatment of inherited disorders of metabolism.
Society for the Study of Inborn Errors of Metabolism
A society created to foster the study of inherited metabolic disorders and related topics, and to promote the exchange of ideas among professionals interested in inherited metabolic disease.
Indication & Usage
Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:
- bone disease
- hepatomegaly or splenomegaly
Important Safety Information
Approximately 15% of patients have developed IgG antibodies, and these patients have a higher risk of hypersensitivity reaction. Therefore periodic monitoring is suggested; caution should be exercised in patients with antibodies or prior symptoms of hypersensitivity. Symptoms suggestive of hypersensitivity occurred in 6.6% of patients, and include anaphylactoid reaction, pruritus, flushing, urticaria, angioedema, chest discomfort, dyspnea, coughing, cyanosis and hypotension.
Reactions related to Cerezyme administration have been reported in less than 15% of patients. Each of the following events occurred in less than 2% of the total patient population. Reported adverse events include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and tachycardia. Adverse events associated with the route of administration include discomfort, pruritus, burning, swelling or sterile abscess at the site at the site of injection.
To report suspected adverse reactions, contact Genzyme at 800-745-4447, option 2 or FDA at 800-FDA-1088 or http://www.fda.gov/Safety/MedWatch
Please see Full Prescribing Information (PDF).